Cipla Ltd. News and Updates

Name: Latest research reports of Cipla Ltd. authored by Sharekhan and published by - Trendlyne research reports.
Item: Cipla Ltd.
Rating: 5
Author: Sharekhan

Keep track of all breaking news on Cipla Ltd. from all sources in a single place.

Load latest

Cipla Ltd.

05 Apr 2024

1517.50

0.66%

US FDA's 6 observations for Cipla's Patalganga unit drags firm's shares down 1.5%

Moneycontrol

Cipla's Patalganga plant manufactures active pharmaceutical ingredients (APIs), the key raw materials for medicines, as well as formulations.

Cipla Ltd.'s price crossed above 200Day SMA today

Cipla Ltd.

31 Mar 2024

1517.50

0.66%

Complex respiratory portfolio propels Cipla towards profitability

Business Today

A report from brokerage firm Sharekhan highlighted key factors contributing to Cipla's upward trajectory, emphasizing the company's strategic focus on complex products and the resultant impact on margins.

Cipla Ltd. is trading above its 200 day SMA of 1509.1

Cipla Ltd.

27 Mar 2024

1517.50

0.66%

Cipla, Sanofi India shares gain on distribution agreement

Moneycontrol

Cipla will be responsible for the distribution of Sanofi India's six central nervous system products, including Frisium, a leading brand in the anti-epileptic medication category

Cipla Ltd. has an average target of 1703.00 from 9 brokers.

Cipla to distribute Sanofi India's CNS products in India

Business Line | 26 Mar 2024

Cipla Ltd.

18 Mar 2024

1517.50

0.66%

Buy Cipla; target of Rs 1700: Sharekhan

Moneycontrol

Sharekhan is bullish on Cipla has recommended buy rating on the stock with a target price of Rs 1700 in its research report dated March 14, 2024.

Number of FII/FPI investors decreased from 1124 to 1085 in Sep 2025 qtr

Cipla Ltd.

14 Mar 2024

1517.50

0.66%

Cipla

Buy: Cipla Ltd.

Recommendation Target

Sharekhan

Cipla Ltd. has an average target of 1703.00 from 9 brokers.

Cipla Ltd.

12 Mar 2024

1517.50

0.66%

Phillip Capital Highlights 12% Earnings Concern For Cipla; Reiterates 'Sell' Rating

NDTV Profit

Cipla Ltd. is trading below its 30 day SMA of 1546.1

Cipla Ltd.

11 Mar 2024

1517.50

0.66%

Cipla stock jumps to all-time high; Nuvama raises target price, sees 18% upside

Moneycontrol

Cipla is aiming to transition from a pure-play pharma company to an integrated health player, per analysts.

Cipla Ltd. has an average target of 1703.00 from 9 brokers.

Cipla Ltd.

02 Mar 2024

1517.50

0.66%

Cipla stock gains; US FDA inspection concludes with zero observations

Moneycontrol

Cipla has completed the transfer of its generics business 'as a going concern on a slump sale basis to Cipla Pharma and Life Sciences Limited', the company told bourses

Cipla Ltd. is trading above its 200 day SMA of 1509.1

Cipla Ltd.

26 Feb 2024

1517.50

0.66%

Cipla Gets CDSCO Nod For Antibiotic To Treat Complicated Urinary Tract Infections

NDTV Profit

Plazomicin is a new intravenous (IV) aminoglycoside indicated for the treatment of Complicated Urinary Tract Infections, including pyelonephritis.

Number of FII/FPI investors decreased from 1124 to 1085 in Sep 2025 qtr

Cipla Ltd.

16 Feb 2024

1517.50

0.66%

Cipla Partners With CSIR-CDRI To Develop Formulation For Fungal Keratitis

NDTV Profit

The collaboration aims to leverage the combined expertise and resources of both organisations to develop a safe and efficacious drug for fungal keratitis, the Mumbai-based drug maker said in a statement.

Cipla Ltd.'s price crossed above 200Day SMA today

Is Cipla Ltd. worth buying?

634 Votes:

Buy 75.71%

Sell 13.72%

Hold 10.57%

RESEARCH REPORTS

Accumulate SEE REPORTS >

pdf

Buy SEE REPORTS >

pdf